...HTX (formerly Cryptome Pharmaceuticals Ltd. ) and the university expanded an August 2006 deal to give HTX rights...
...for acute respiratory distress syndrome (ARDS) this quarter. Further terms were not disclosed. HTX and Cryptome...

...CRP is in-licensing the university's CR014, a peptide that has broad-spectrum activity in vascular leak. Cryptome Pharmaceuticals Ltd....

...preventing or treating inflammatory or traumatic injury of the brain. CRP will own resulting compounds. Cryptome Pharmaceuticals Ltd....

...discovery technology to validate one of Xantos' angiogenic therapeutic leads. CRP is eligible for milestones. Cryptome Pharmaceuticals Ltd....

...of fragments of the proteins. CRP will have commercialization rights to resulting IP and compounds. Cryptome Pharmaceuticals Ltd....

...for identifying and isolating low-abundance human proteins. CRP will have commercialization rights to resulting therapeutics. Cryptome Pharmaceuticals Ltd....

...as well as cellular infiltrate in a mouse model of adult respiratory distress syndrome (ARDS). Cryptome Pharmaceuticals Ltd....

...55% delay in clotting at 5 minutes to about a 40% delay at 60 minutes. Cryptome Pharmaceuticals Ltd....

...for small protein fragments with therapeutic potential for cardiovascular indications. Financial terms were not disclosed. Cryptome Pharmaceuticals Ltd....

...throughput protein fragment discovery platform and the Institute's compound libraries. CRP will screen the libraries. Cryptome Pharmaceuticals Ltd....